AlphAIAlphAI — Financial news for AI agents
stockstotrade.comSEP 242 min read$TWST

TWST Stock Jumps As Lilly AI Deal And Target Hike Fuel Momentum

Twist Bioscience (TWST) shares rose 16.21% after announcing an AI deal with Eli Lilly and a price target increase to $160 by Leerink. The company reported Q3 revenue of $118.4M, gross margin of 52%, and a net loss of $35.1M. TWST's stock has climbed from $139 to $184 since late August 2026.

Original reporting
stockstotrade.com
Published Sep 24, 2026, 8:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
TWST Stock Jumps As Lilly AI Deal And Target Hike Fuel Momentum — source image
Source · stockstotrade.com
Decision brief

The 30-second read

$TWSTBullishHigh
01

Why it matters

The Lilly AI data deal and Leerink target hike constitute fresh, material news that sparked a 16% price surge, indicating strong short‑term trader interest.

02

Market read

The announcement directly moved TWST shares and signals broader AI‑biotech synergy, relevant for traders focused on biotech and AI themes.

03

What to watch

Cash runway is sufficient, but the deal's revenue contribution timeline is uncertain.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Twist Bioscience (NASDAQ:TWST) is a synthetic‑biology company that supplies DNA‑based products and services.

Company-level read

Ticker impact

$TWSTBullishHigh confidence
Context

Twist Bioscience announced a new AI/ML data partnership with Eli Lilly and received a Leerink price‑target increase, driving a 16% intraday jump.

Expected impact

Expect continued upside toward $190‑$200 in the next few days if volume remains strong.

Evidence & confidence

Both a strategic pharma deal and an analyst upgrade are first‑report events that moved the stock sharply.

Market effects

Sector

Highlights growing demand for AI‑enabled biotech services, potentially benefitting other synthetic‑biology firms.

Regional

Positive for US biotech and AI‑related equities.

Global

Shows pharma‑AI collaborations are becoming a global trend.

Counterpoint

What could challenge this read

The partnership may be limited in scale and the company remains loss‑making; a pull‑back could occur if results lag.

Key entities

  • company
    Twist Bioscience

    Synthetic‑biology firm providing DNA‑based products.

  • company
    Eli Lilly

    Pharma partner launching the AI/ML data collaboration.

  • analyst_firm
    Leerink

    Raised price target to $160 and upgraded to Outperform.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 25
$CDNAMed

Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY

Several biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.

rttnews.com2 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Shares Soar 10.27% to New High, Extending a Remarkable 493% Yearlong Rally Fueled by AI

Twist Bioscience Corp. shares rose 10.27% to $174.78, extending a 493% yearlong rally. The surge follows a data-services agreement with Eli Lilly's AI-driven drug discovery platform, TuneLab. The company raised full-year revenue guidance to $456M-$457M and aims for adjusted EBITDA breakeven by Q4. Despite strong growth, Twist remains unprofitable with a negative EBIT margin of 31.5%.

ibtimes.com.au2 min
SEP 19
$TWSTHigh

TWST Jumps As Twist Bioscience Lands Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 7.1% following a deal with Eli Lilly for AI-driven drug discovery. Analysts see strong short-term momentum, with price targets at $160 (Leerink) and $144 (UBS). The company has high revenue growth but remains unprofitable, with Q3 free cash flow at -$8.6M. Balance sheet is stable, with a current ratio of 2.7.

timothysykes.com2 min